Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Following the discovery of the human kinome, protein kinases have become the second most important group of drug targets as they can be modulated by small ligand molecules. Moreover, orally active protein kinase inhibitors have recently reached the market and there are many more in clinical trials. The lack of treatments for neurodegenerative diseases has increased human and financial efforts in the search for new therapeutic targets that could provide new effective drug candidates. The importance of kinases in the molecular pathway of neuronal survival is under study, but different key pathways have been described. New roles for the old casein kinases 1 and 2, currently known as protein kinases CK1 and CK2, have recently been discovered in the molecular pathology of different neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases and amyotrophic lateral sclerosis. The search for specific inhibitors of these enzymes has become an important challenge for the treatment of these devastating diseases. The role of these two kinases in the molecular pathology of different neurodegenerative diseases together with different chemical families that are able to more or less specifically inhibit CK1 and CK2 are discussed in this review. © 2010 Wiley Periodicals, Inc. Med Res Rev 31:924‐954, 2011
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“Compound IC261 is also able to reduce the formation of bA peptide acting during the g-secretase cleavage(46) and still reduces AKt phosphorylation,(64) which is a very important pathway in processes, such as cell metabolism, cell cycle control, and cancer.(65) Two imidazole derivatives have also been reported to be po…”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
The casein kinase 1 family: participation in multiple cellular processes in eukaryotes
Knippschild, U., Gocht, A., Wolff, S., Huber, N., Löhler, J., & Stöter, M. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2004.12.011 · Cited by 601
Hanger, D. P., Byers, H. L., Wray, S., Leung, K.-Y., Saxton, M. J., Seereeram, A., Reynolds, C. H., Ward, M. A., & Anderton, B. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703269200 · Cited by 455 · cited 1×
“A recent study demonstrated that CK1d and GSK-3 phosphorylate at least 15 sites that are also phosphorylated in the paired helicoidal filaments (PHF) of tau from an Alzheimer brain.(45) A combination of CK1d and GSK-3 activities could account for more than three-quarters of the Ser/Thr phosphorylation sites identified…”
BackgroundCasein kinase I transduces Wnt signals
Peters, J. M., McKay, R. M., McKay, J. P., & Graff, J. M. (1999) · Nature · doi:10.1038/43830 · Cited by 447 · cited 1×
“CK1 is a Ser/Thr kinase that is ubiquitously expressed in eukaryotic organisms.(20) So far, at least seven isoforms (a, b, g1-3, d, and e) and their various splice variants have been characterized in different organisms.”
BackgroundSelective Inhibition of Casein Kinase 1ϵ Minimally Alters Circadian Clock Period
Walton, K. M., Fisher, K., Rubitski, D., Marconi, M., Meng, Q.-J., Sládek, M., Adams, J., Bass, M., Chandrasekaran, R., Butler, T., et al. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.151415 · Cited by 184
Badura, L., Swanson, T., Adamowicz, W., Adams, J., Cianfrogna, J., Fisher, K., Holland, J., Kleiman, R., Nelson, F., Reynolds, L., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.122846 · Cited by 176
Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800109e · Cited by 139
Cited by
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis
Knippschild, U., Krüger, M., Richter, J., Xu, P., GarcÃa-Reyes, B., Peifer, C., Halekotte, J., Bakulev, V., & Bischof, J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00096 · Cited by 272
Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159
“Meanwhile, with Tideglusib [130], the levels in the selected age groups were pointed out to be too low to be reliably quanti fi ed [192, 193].”
BackgroundCircadian gene variants in cancer
Kettner, N. M., Katchy, C. A., & Fu, L. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.914808 · Cited by 147
Bacci, A., Runfola, M., Sestito, S., & Rapposelli, S. (2021) · Antioxidants · doi:10.3390/antiox10030367 · Cited by 23
Metadata
- Authors
- Perez, D. I., Gil, C., & Martinez, A.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2011-10-12
- Volume
- 31
- Issue
- 6
- Pages
- 924-954
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2080166273
- Cited by
- 155
- References
- 10
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. https://app.cochat.ai/papers/10.1002/med.20207
- The paper
- Perez, D. I., Gil, C., & Martinez, A. (2011). Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Medicinal Research Reviews. https://doi.org/10.1002/med.20207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.